MaxCyte (NASDAQ:MXCT) Price Target Cut to $5.00 by Analysts at Craig Hallum

MaxCyte (NASDAQ:MXCT) had its price target reduced by equities researchers at Craig Hallum from $7.00 to $5.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other equities research analysts have also recently commented on the stock. Wall Street Zen cut shares of MaxCyte from a “hold” rating to a “sell” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MaxCyte presently has a consensus rating of “Hold” and an average price target of $5.50.

MaxCyte Trading Down 3.6%

Shares of NASDAQ MXCT traded down $0.03 during midday trading on Wednesday, reaching $0.71. The company’s stock had a trading volume of 766,681 shares, compared to its average volume of 1,114,390. The stock has a 50 day simple moving average of $0.88 and a 200-day simple moving average of $1.33. The stock has a market capitalization of $76.06 million, a price-to-earnings ratio of -1.62 and a beta of 1.22. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $3.10.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $6.76 million during the quarter, compared to analysts’ expectations of $9.16 million. MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. As a group, equities analysts anticipate that MaxCyte will post -0.42 EPS for the current year.

Institutional Trading of MaxCyte

A number of large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in shares of MaxCyte by 39.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after acquiring an additional 10,263 shares during the period. Kwmg LLC raised its holdings in shares of MaxCyte by 75.8% in the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after purchasing an additional 11,135 shares during the period. Prudential Financial Inc. acquired a new stake in MaxCyte in the 2nd quarter valued at about $26,000. State of Wyoming acquired a new stake in MaxCyte in the 2nd quarter valued at about $38,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in MaxCyte during the second quarter worth about $40,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte News Summary

Here are the key news stories impacting MaxCyte this week:

• Positive Sentiment: Healthy cash runway — MaxCyte reported $155.6M in cash, cash equivalents and investments at year‑end 2025 and said it expects to finish 2026 with at least ~$136M, which should fund operations and strategic initiatives. GlobeNewswire Release
• Positive Sentiment: 2025 revenue at the top of prior prelim range — Full‑year 2025 revenue came in at $33.0M, at the top of MaxCyte’s earlier preliminary range, showing execution on prior guidance. GlobeNewswire Release
• Neutral Sentiment: Earnings call and transcripts available — Management reviewed results and strategy on the Q4 2025 call; full transcripts are posted for investors to evaluate commentary on commercialization progress and program timing. Seeking Alpha Transcript
• Neutral Sentiment: Short‑interest data shown in aggregators appears inconsistent/zero and should be treated as unreliable until exchanges confirm actual figures. (Multiple summary entries flagged anomalous short‑interest values.)
• Negative Sentiment: Q4 missed consensus — MaxCyte reported EPS of $(0.09) vs. consensus ~(0.08) and Q4 revenue of ~$6.75–7.3M, well below analyst expectations of ~$9.16M; net margin and ROE remain deeply negative. MarketBeat Earnings Summary
• Negative Sentiment: 2026 guidance implies a modest revenue decline — Management guided 2026 revenue of $30–32M (Core $25–27M; SPL program ~$5M), below 2025’s $33M, which may signal slower near‑term growth and is likely weighing on sentiment. GlobeNewswire Release

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.